Knight Signs New Exclusive AmBisome Agreement with Gilead in Brazil

Knight Therapeutics Inc. a leading pan-American (ex-US) specialty pharmaceutical company, announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. for the commercialization of AmBisome (liposomal amphotericin B) in Brazil. The agreement will be effective starting January 1, 2021.

“We’re excited to renew this established partnership and we’re grateful for Gilead’s continued confidence in the Knight team” said Samira Sakhia, President and Chief Operating Officer of Knight. “Our Brazilian team launched AmBisome in Brazil over 20 years ago and we look forward to continuing the great work they have been doing with patients and physicians.”

“The signing of this new agreement extends the long-standing collaboration between Gilead and Grupo Biotoscana and validates Knight’s valuation of the GBT acquisition” said Amal Khouri, VP Business Development of Knight.

“Gilead highly values the ongoing partnership with GBT to help address medical needs in Brazil,” said Ahmed Afifi, Vice President and Region Head Latin America at Gilead Sciences. “With this new agreement, we look forward to continuing our collaboration with the expanded GBT/Knight team to help enable access to AmBisome to Brazilian patients.”